Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
Seventh Indication Secured For Blockbuster
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
You may also be interested in...
The Swiss major is sticking to a bolt-on M&A strategy in its key areas and a deal in the obesity space is highly unlikely unless it involves "leapfrogging" what is already available.
There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.
Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.